Drug Profile
Research programme: serine protease inhibitors - Pharis biotec
Alternative Names: LEKTI - Pharis Biotec; Lympho-epithelial Kazal type inhibitor; SPINK5 - Pharis BiotecLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pharis Biotec
- Class Peptides
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atopic-dermatitis in Germany